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NEW INVESTIGATORS WIN
BBMT EDITORIAL AWARDS
Two medical scientists are the re-
cipients of new investigator editorial
awards, based on their articles pub-
lished this past year in Biology of
Blood and Marrow Transplantation.
• The recipient of the George Santos
Award for best clinical science arti-
cle is Geoffrey W. Chan, MD, of
Tufts-New England Medical Cen-
ter, Boston.
• The recipient of the Ernest McCul-
loch & James Till Award for best
basic science article is Stephen C.
Jones, PhD, of Jefferson Medical
College, Philadelphia.
The annual awards, each including
a $5,000 prize, are supported by ed-
ucational grants from StemCell Tech-
nologies Inc. and StemSoft Software
Inc., Vancouver. They were pre-
sented by Robert Korngold, PhD, ed-
itor of the journal, and Gary Racine,
general manager of StemSoft Soft-
ware, at the 2004 Tandem BMT Meet-
ings in Orlando.
Dr. Chan’s winning article was
“Persistence of Host Dendritic Cells af-
ter Transplantation is Associated with
Graft-versus-Host Disease,” which ap-
peared in BBMT Volume 9, Number 3.
Dr. Jones’ winning article was
“Post-Hematopoietic Cell Transplanta-
tion Control of Graft-versus-Host Dis-
ease by Donor CD425 T-Cells to
Allow an Effective Graft-versus-Leuke-
mia Response,” which appeared in
BBMT Volume 9, Number 4.
Recipients of the two annual awards
may not be more than five years past
a graduate or post-doctoral program
or a clinical research fellowship, or
currently active in a training program
as a clinical resident or fellow, post-
doctoral fellow, medical student, grad-
uate student, or undergraduate stu-
dent.
The judging committee is made up
of the BBMT Editorial Board and the
ASBMT Publications Committee.
FOUNDER OF NBMT-LINK WINS
ASBMT PUBLIC SERVICE AWARD
Myra Jacobs, executive director
and founder of the National Bone
Marrow Transplant Link, is the recipi-
ent of the 2004 ASBMT Public Service
Award.
Her not-for-profit organization, known
as the “nbmtLINK” to those familiar
with and depending on its services,
provides information and support for
bone marrow and stem cell trans-
plant patients. It works with patients,
their families, and health profession-
als, connecting them to resources to
help them through difficult therapies.
She was presented the Public Ser-
vice Award at the 2004 Tandem BMT
Meetings in Orlando. The award is
supported by an unrestricted educa-
tional grant from Pfizer, Inc.
2004 TANDEM BMT MEETINGS
AUDIOCASSETTES AVAILABLE
Audiocassettes can be purchased
for all plenary and concurrent scien-
tific sessions, workshops, and oral
abstract sessions from the Tandem
BMT Meetings this past February in
Orlando. Also available are presenta-
tions in the conferences of the trans-
plant nurses, BMT pharmacists, clinical
research associates, and BMT center
administrators. Information is available
and online purchase can be made at
www.CMEunlimited.org/bmt.
BEST ABSTRACTS CHOSEN
FROM RECORD 314 SUBMITTED
A record 314 abstracts from 31
countries were accepted for the Tan-
dem BMT Meetings in Orlando.
The abstract review committees se-
lected six for awards.
Winners of the ASBMT Best Abstract
Award for Outstanding Basic Science
Research were:
• Andreas Beilhack, MD, Stanford
University, Stanford, Calif.
• Stephanie Muriglan, Memorial Sloan-
Kettering Cancer Center, New York,
N.Y.
• Arnon Nagler, MD, PhD, Tel Aviv
University, Tel Aviv, Israel
Winners of the IBMTR/ABMTR Mor-
timer M. Bortin Award for Outstand-
ing Clinical Research were:
• Katharine C. Hsu, MD, PhD, Memo-
rial Sloan-Kettering Cancer Center,
New York, N.Y.
• Vincent T. Ho, MD, Dana-Farber
Cancer Institute, Boston, Mass.
• Michelle M. Bishop, PhD, University
of Florida, Gainesville, Fla.
The ASBMT best abstract awards
are supported by an unrestricted ed-
ucational grant from SuperGen. The
IBMTR/ABMTR best abstract awards
are supported by Gambro BCT.
ABSTRACTS POSTED ONLINE
Abstracts presented at the 2004
Tandem BMT Meetings were pub-
lished in a special supplement to the
February 2004 issue of Biology of
Blood and Marrow Transplantation
(Vol. 10, No. 2, Supplement). They
also can be viewed online at the
ASBMT Web site, www.asbmt.org.
MESENCHYMAL CELL CONFERENCE
SET FOR OCTOBER IN NEW ORLEANS
Mesenchymal stem cell biology,
stem cell plasticity, and cell therapy
for cardiac, pulmonary, and neuro-
logic diseases will be topics at the 4th
Annual Mesenchymal and Nonhema-
topoietic Stem Cells Conference on
Oct. 14-15 at the Wyndham Hotel in
New Orleans. ASBMT is a co-sponsor.
Information and registration details
are online at www.neworleansmsc
meeting.org.
RESEARCH AWARDS ANNOUNCED
FOR ACQUIRED MARROW FAILURE
New investigators and those with
established track records conducting
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research in acquired bone marrow
failure diseases—aplastic anemia, my-
elodysplastic syndromes and paroxys-
mal nocturnal hemoglobinuria—can
apply for two-year awards of $60,000
each from the Aplastic Anemia & MDS
International Foundation.
The deadline is Nov. 30, 2004. In-
formation and applications are online
at www.aamds.org/grants.shtml.
MULTIPLE MYELOMA REVIEW
ACCEPTED BY CLEARINGHOUSE
The ASBMT evidence-based review
on multiple myeloma has been ac-
cepted for listing with the National
Guideline Clearinghouse.
The NGC is a resource for evidence-
based clinical practice guidelines for
physicians and other health profes-
sionals, health plan managers and
purchasers, and integrated delivery
systems. It provides ready online ac-
cess to objective, detailed information
on clinical practice guidelines.
NGC is a jointly sponsored pro-
gram of the Agency for Healthcare
Research and Quality (AHRQ) and the
U.S. Department of Health and Hu-
man Services (HHS), in partnership
with the American Medical Associa-
tion (AMA) and the American Associ-
ation of Health Plans–Health Insur-
ance Association of America (AAHP-
HIAA).
The multiple myeloma evidence-
based review concluded that stem cell
transplantation is more effective than
standard chemotherapy as first-line
therapy for patients who require treat-
ment for multiple myeloma. The review
was published in the January 2003
issue of Biology of Blood and Mar-
row Transplantation (Vol. 9, No. 1).
UNIVERSITY OF MICHIGAN PHYSICIAN
WINS ASBMT/ESP PHARMA AWARD
An assistant professor of internal
medicine at the University of Michi-
gan Medical School is the recipient
of a new investigator award from
ASBMT and ESP Pharma.
Pavan Reddy, MD, is a member of
the adult blood and marrow transplant
program in the university’s Compre-
hensive Cancer Center. His research
concerns the role of antigen-presenting
cells in mediating a graft-versus-leuke-
mia (GvL) effect after experimental allo-
geneic bone marrow transplantation.
The $25,000-per-year award is re-
newable in 2005.
Dr. Reddy will study the role of host
antigen-presenting cells (APCs) and
pro-inflammatory cytokines in induc-
ing a GvL response after transplanta-
tion. Techniques of eliminating APCs
from the host have been suggested
as a way of preventing graft-versus-
host disease (GvHD).
To test the impact of eliminating
APCs on the GvL effect, Dr. Reddy will
generate chimeric recipient mice in
which APCs cannot present tumor an-
tigens to the donor T cells. He expects
that, in the absence of host APCs, the
recipient animals will develop neither
a GvL nor a GvHD response.
Dr. Reddy also will look at how tu-
mor antigen expression and pro-inflam-
matory cytokines contribute to the GvL
response. Further experiments in chi-
meric mice are expected to determine
whether foreign antigens must be ex-
pressed on both the APCs and tumor
cells for an effective GvL response to oc-
cur. Some animals will receive treatment
to block pro-inflammatory cytokines, to
see if this helps to preserve the GvL effect
while blocking the GvHD response.
M. D. ANDERSON INSTRUCTOR WINS
ASBMT/FUJISAWA INVESTIGATOR AWARD
An instructor at the M. D. Anderson
Cancer Center at the University of
Texas, Houston, is the recipient of a
new investigator award from ASBMT
and Fujisawa Healthcare.
Sijie Lu, PhD, is a member of the
cancer center’s Department of Blood
and Marrow Transplantation, Section
of Transplant Immunology. His re-
search concerns ways of eliciting do-
nor cytotoxic T-lymphocytes (CTLs)
specifically targeted against a previ-
ously identified leukemia-associated
antigen, termed PR1. The $25,000-
per-year award is renewable in 2005.
The first step in Dr. Lu’s research
will be to determine whether mi-
crobeads coated with synthetic PR1-
HLA protein complexes can be used
to obtain and purify CTLs targeted
directly against PR1 from healthy do-
nor lymphocytes. This will be fol-
lowed by a series of experiments to
engineer artificial antigen-presenting
cells—along with co-stimulatory mole-
cules—to expand the PR1-specific CTLs.
The resulting CTLs will then be tested
for their ability to kill leukemic cells.
The overall goal of Dr. Lu’s research
is to develop an efficient way of se-
lecting PR1-specific CTLs for use in
treating patients whose leukemia has
relapsed after initial bone marrow
transplantation. The specific cells
should provide an enhanced graft-
versus-leukemia effect without induc-
ing graft-versus-host disease. The use
of artificial antigen-presenting cells
may provide a quicker way of gener-
ating high-quality CTLs for leukemia
treatment, and possibly for cellular
therapy of other types of diseases.
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